Применение статинов – парадигма профилактики и лечения атеросклеротических заболеваний (фокус на аторвастатин)

В статье обсуждаются перспективы применения статинов в целях вторичной профилактики, отмечается их высокая эффективность за счет выраженной гиполипидемической активности и множественности плейотропных эффектов. Цель. Изучить гиполипидемическую активность и безопасность генерика аторвастатина (Липтонорма®) в сравнении с оригинальным препаратом аторвастатина – Липримаром®. Материал и методы. 30 больных ИБС и гиперхолестеринемией (ГХС) рандомизированно получали в течение 12 недель оригинальный аторвастатин и его генерик. У пациентов определяли содержание липидов крови, печеночных ферментов и креатинфосфокиназы. Результаты. Уровни общего холестерина (ОХС) в группах Липтонорма® и Липримара® снизились с 7,7±1,25 ммоль / л до 4,4±0,8 ммоль / л и c 6,9±1,3 до 4,6±0,7 ммоль / л соответственно; ХС липопротеидов низкой плотности – с 5,4±1,4 до 2,7±0,7 и с 4,7±1,3 ммоль / л до 2,7±0,7 ммоль / л соответственно; триглицеридов с 1,7±0,7 ммоль / л до 1,2±0,3 ммоль / л и с 1,9±1,0 до 1,2±0,4 моль/л соответственно. Содержание ХС липропротеидов высокой плотности увеличилось в обеих группах с 1,03±0,25 до 1,13±0,21 и с 1,32±0,31 до 1,37±0,28 ммоль / л соответственно. Динамика липидных показателей к концу исследования была высоко достоверной и сопоставимой в обеих группах. Ферментные показатели крови к концу исследования практически не изменились. Заключение. Генерик аторвастатина Липтонорм® оказывает аналогичное влияние на липидные показатели крови в сравнении с оригинальным аторвастатином.

1. Statins may benefit early multiple sclerosis; http://www.ttmed. com/cardiology.

2. Chan KA, Andrade SE, Boies M, et al. Inhibitors of hydroxymethylglutafyl-coenzyme A reductasа and risk of fracture among older women. Lancet 2000; 355: 2185-8.

3. Mundy G, Garrett R, Harris S, et al. Simvastatin of bone formation in vitro and in rodents by station. Science 1999; 286(5446): 1946-9.

4. De Sutter J, Tavemier R, De Buyeiere M, et al. Lipid lowering drugs and recurrences of life-threatening ventricular arhythmias in high-risk patients. JACC 2000; 36: 773-5.

5. Wolozin В, Kellman W, Celesta GG, et al. Decreased prevalence of Alzheimer disease associated with 3-hydro-3-methylglutyr coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1434-43.

6. Pyorala K, Ballantyne CM, Gumbiner B, et al. Scandinavian Simvastatin Survival Study (4S). Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004; 27(7): 1735-40.

7. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159(22): 2627-8.

8. Wenke K, Meiser В, Thiery J, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation. A four year randomized trial. Circulation 1997; 1398-402.

9. Valantine HA, Schoeder JS. HMG-Co A reductase inhibitors reduce transplant coronary artery disease and mortality. Evidence for antigen-independent mechanism. Circulation 1997; 96(5): 1370-3.

10. Katznelson S, Kobushigava JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Inс 1995; 4S: Suppl 52: 112-5.

11. Bateson MC. Simvastatin and ursodeoxychlolic acid for rapid gallstone dissolution. Lancet 1990: 336: 1196-9.

12. Ferrier KE, Muhlmann MH, Baguer J-Ph, et al. Intensive cholesterol reduction lowers blood pressure and large artery - stiffness in isolated systolic hypertion. JACC 2002; 34: 1020-5.

13. Lorenzo EDI, Indorf C, Perrino D, et al. HMG-CoA reductase inhibitors prevent left ventricular hypertrophy by up-regulation of Cdk4 levels. Eur Heart J 2000; 2l(Suppl): 261.

14. Jack H, Zorgberg GL, Melt SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.

15. Achenbach S, Ropers D, Pahle К, et al. Influence of lipid-lowering therapy on progress of coronary artery calcification. Circulation 2002; 106: 1077-82.

16. Liebe V. Statin therapy of calcific aortic stenosis: hype or hope? Eur Heart J 2006; 27:773-6.

17. Shavelle DM, Takasu J, Budoff MJ, et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359(9312): 1125-6.

18. Salonen R, Nyysonen K, Porkkala-Sarataho E, Salonen JT. The / Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids oxidation resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995; 76(9): 34-9.

19. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 337(9262): 1063-8.

20. Cipollone F, Fazia M, Lezzi M, et al. Simvastatin stabilizes atherosclerotic plaques by inhibiting cyclooxygenase dependent metalloproteinase activity. Atherosclerosis 2002; 3: 92.

21. Tonkin AM, Colquhoun I, Emberson J, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet 2000; 336(9245): 1871-5.

22. Аронов Д.М., Бубнова М.Г., Перова Н.В. и др. Влияние ловастатина на динамику липидов и апопротеинов сыворотки крови после максимальной физической нагрузки в период пищевой липемии у больных ишемической болезнью сердца. Кардиология 1995; 3: 38-9.

23. Бубнова М.Г., Аронов Д.М., Перова И.В. и др. Правастатин в коррекции атерогенной экзогенно-индуцированной постпрандиальной гиперлипидемии. Кардиология 2002; 7: 27-9.

24. Перова НВ, Бубнова МГ, Аронов Д.М. Влияние ловастатина на концентрацию липидов и липопротеидов сыворотки крови после алиментарной жировой нагрузки у больных ишемической болезнью сердца. Кардиология 1993; 4: 8-10.

25. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin Treatment Increases Collagen Content and Decreases Lipid Content, Inflammation. Metalloproteinases and Cell Death in Human Carotid Plaques. Circulation 2001; 103: 926-33.

26. Park JK, Mutter DN, Gueler F, et al. Dose dependent anti-inflammatory effects of rosuvastatin: prevention of leukocyte infiltration, INOS induction and collagen expression in angiotensin II-induced nephrosclerosis. Eur Heart J 2003; 24(Supрl): 690.

27. Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur Heart J 2001; 22: 2135-7.

28. Ridker PM. Inflammatory Biomarkers. Statins and the Risk of Stroke. Circulation 2002; 105: 2583-5.

29. Sager P, Melani L, Lipka L, et al. C-reactive protein is reduced during ezetimibe coadministration with simvastatin in patients with primary hypercholcsterolaemia. Eur Heart J 2003; 24(Suppl): 690.

30. Semb AG, Wan Wissen S, Ueland T, et al. Pleotropic effects of statins. Increased central inflammatory marker CD40 ligand early in atherosclerosis in familial hypercholesterolaemic patients. Eur Heart J 2003; 24(Suppl): 689.

31. von Nieuw Amerongen CP, Vermeer MA, Negre-Aminou P, et al. Simvastatin Improves Disturbed Endothelial Barrier Function. Circulation 2000; 102: 2803-9.

32. Aengevaeren NRM, Kmon AA, Stulenhoff AEH, et al. Low density lipoprotein aphersis improves regional myocardial perfusion in patient with hypercholesterolemia and extensive coronary artery disease. JACC 1998; 28: 1696-704.

33. Ofner P. Effects of simvastatin on endotelial function of hypertensive, non-hyperlipidaemic. In: 14-th International Simposium Drugs Effecting Lipid Metabolism. New York 2001; 98.

34. Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholestcrolemic patients. JACC 1996; 27(Suppl): 413A.

35. Аронов Д.М. Каскад терапевтических эффектов статинов. Кардиология 2004; 10: 85-92.

36. Jones PH. Comparing HMG-CoA reductase inhibitors. Clin Cardiol 2003; 26(Suppl 1): 115-20.

37. Аронов Д.М. Лечение и профилактика атеросклероза. Москва «Триада» 2000; 309 с.

38. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average of lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003; 361(9364): 1149-58.

39. Sacks FM, Pasternak RC, Gibson CM, et al., for the Harvard Atherosclerosis Reversibility Project (HARP) Group. “Effect on coronary atherosclerosis of decrease in plasma cholesterol concentration in normocholesterolaemoc patients”. Lancet 1994; 344(1831): 1182-6.

40. LIPID Study Group. “Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomised trial in patients with previous acute myocardial infarction and/or unstable angina pectoris”. Am J Cardiol 1995; 76: 474-9.

41. Schwartz GG,Ollson AG, Ezekowitz MD, et al for the Miocardial Ishemia Reduction with Aggressive Cholesterol Lowering(MIRACL) Study Investigators. Effect of atorvastatin on early recarrent ishemic events in acute coronary syndroms. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285:1711-8.

42. Heart Protection Study Collaborative Group “MRS/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 23-4.

43. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease the Scandinavian Simvastatin Survial Study (4S). Lancet 1994; 344: 1383-9.

44. Athyros VG, Papageorgiou AA. Treatment with atorvastatin to the National Cholesterol Educational Program Goal Versus “Usual” care in secondary heart Disease Prevention. The Greek Atorvastatin and Coronary-heart-disease Evaluation (Greace) Study. Cur Med Res Opin 2002; 18(4): 220-8.

45. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2006; 350(15): 1495-504.

46. Joint ISA – National LIPID (NLA) Symposium Report of the TASK FORCE ON STATIN SAFETY. Atherosclerosis 2006; 7(3): 1-2.

47. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Диагностика и лечение стабильной стенокардии в Российской Федерации. Международное исследование ATP-angina treatment pattern. Кардиология 2003; 43(5): 9-16.

48. Явелов И.С., Грацианский Н.А. Российский регистр острых коронарных синдромов. Лечение и исходы в стационаре при остром коронарном синдроме без подъемов сегментов S-T. Кардиология 2003; 43: 1223-35.

49. Аронов Д.М., Ахмеджанов Н.М., Гутковская А.А. и др. Эффективность мероприятий по борьбе с факторами риска у больных КБС, проводимых врачами первичного звена (по результатам опросов). РКЖ 2006; 3: 34-40.

50. Шальнова СА, Деев АД, Карпов ЮА от имени участников исследования ПРЕМЬЕРА. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врачакардиолога. Кардиоваск тер профил 2006; 5(2): 73-80.

51. Colhoun HM, Betteridge DJ, Durrington PN, et al. CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebocontrolled trial. Lancet 2004; 364(9435): 685-96.

52. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome. Circulation 2004; 110:(9) 1061-8.

53. Schuler G, Hambrecht R, Schliert G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992; 86(1): 1-11.

54. Niebauer J, Velich T, Hambrecht DR, et al. 6 years of intensive physical exercise and low fat diet: effects on progression of coronary artery disease. Circulation 1995; 92(Suppl.I): 398.

55. Levy RI, Brensike J, Epstein SE, et al. The influence of changes in lipid values induced by cholestiramine and diet on progression of coronary artery disease: results of the NLBI Type II Coronary Intervention Study. Circulation 1984; 69(2): 325-37.

56. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestiramine, in the St. Thomas Atherosclerosis Regression Study (STARS). Lancet 1992: 339: 563-9.

57. Blankenhorn DH, Azen SP, Kramsch DK, et al. The MARS Research Group. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119(10): 969-76.

58. Waters D, Higginson L, Gladstone P, et al. The CCAIT Study Group. «Effects of monotherapy with on HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994: 89: 959-68.

59. Jukema JW, Bruschke VG, van Boven RJ, et al. Effects at lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Statin Study (REGRESS). Circulation 1995: 91: 2528-40.

60. Herd JA, Ballantyne ChM, Farmer JA, et al. Effect of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and coronary atherosclerosis study [LCAS]). Am J Cardiol 1997; 80: 278-86.

61. Sacks FM, Pfeffer MD, Nove LA, et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.

62. Ericsson C-G, Hamsten A, Nillsson J, et al. Angiographic assessment of effect of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996; 347(9005): 849-53.

63. Buchwald H, Matts JP, Fitch LL, et al. for the Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. Changes in sequential coronary arteriograms and subsequent coronary events. JAMA 1992; 268(11): 1429-33.

64. Nissen S, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004; 291(9): 1071-80.

65. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very highintensity statin therapy on regression of coronary atherosclerosis; the ASTEROID trial. JAMA 2006; 295(13): 1583-4.

66. Shepherd J, Gobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study G. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333 (20): 1301-7.

67. Dawns JR, Beere PA, Whitny E, et al. Desing and rationale of the Air Fors Texas corcnary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997; 80: 287-393.